Efficacy and Safety of Datopotamab Deruxtecan in Patients with Pretreated Advanced/Metastatic NSCLC with Actionable Genomic Alterations By Ogkologos - January 27, 2025 355 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TROPION-Lung05 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Adopts a Positive Opinion for a New Route of Administration Together with a New Pharmaceutical Form and a New Strength for Isatuximab National Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients with Advanced ROS1-positive NSCLC MOST POPULAR Rate of Suicides Related to Cancer Is Declining February 17, 2021 EMA’s Safety Committee Has Concluded That the Benefits of Ifosfamide Solutions... March 16, 2021 How Early Cancer Detection and Diagnosis Saved My Life Twice: A... December 27, 2023 Tarlatamab Demonstrates Sustained Clinical Benefit and Potential Findings of Intracranial Activity... September 10, 2024 Load more HOT NEWS FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC with High... Good News and Cautions about Pregnancy for Childhood Cancer Survivors Workout Wednesday – Upper Body Stretches Opinion: “We’ve been pushing for change for 20 years. We’re not...
